Epividian at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Epividian brings 2 presentations to IDWeek 2026 in Washington. Its program draws on the OPERA cohort to study HIV treatment and hepatitis C screening. One analysis follows virologic outcomes on dolutegravir/lamivudine after a break in treatment, and another uses clinical decision support to call back people at higher risk of hepatitis C for testing.
| Organization | IDWeek 2026 Attendance |
|---|---|
Epividian Raleigh, NC | |
Clinical data company combining research, technology and clinical reporting for practices, researchers and public health agencies. | Poster Fri Oct 23 12:15pm–1:30pm Virologic Outcomes of Individuals Prescribed Dolutegravir/Lamivudine After an Oral Antiretroviral Therapy Treatment Interruption: Findings from the OPERA Cohort Poster Sat Oct 24 12:15pm–1:30pm Recalling Individuals at Higher Risk of HCV Acquisition for Screening Using a Clinical Decision Support System: Encouraging Findings from the OPERA Cohort |
Instantly find 20 buyers from Epividian
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction